Even with those alarming numbers, the US FDA approvals of disease-modifying therapies (DMTs) such as Leqembi (lecanemab) and Kisunla (donanemab) for select patients provide reason for optimism.

WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...

US market introduction of the CNSide® CSF diagnostics platform, with first national coverage agreement with UnitedHealthcare Presented positive RESPECT-LM Ph1 clinical trial results HOUSTON, Oct. 30, ...

UniQure shares soared on positive AMT-130 Huntington's disease data, but plunged after the FDA reversed its stance on ...

Recall, at the 2025 SNO/ASCO CNS Metastases conference in August, ReSPECT-LM Phase 1 single dose escalation trial data showed: REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically ...

Gilead Sciences, Inc. today announced the Phase 3 ASCENT-07 study investigating Trodelvy® (sacituzumab govitecan-hziy) versus chemotherapy as a first-line treatment post-endocrine therapy in ...

Presented positive data from Phase 1 clinical trials with ARV-102 in healthy volunteers and patients with Parkinson’s disease - ...

Backed by Nvidia and Intel, Twelve Labs builds A.I. that can search, summarize and analyze video content across sectors.

Imagine a surgeon in the middle of a complex operation, able to get instant biochemical feedback not from a lab down the hall, but from the very tool in their hand. This vision is now one step closer ...

UCSF researchers are studying whether large language models, a type of artificial intelligence (AI), can analyze the clinical notes of multiple physicians and other care providers to improve the ...

CSF oligoclonal bands is a test ordered by physicians when serious health concerns related to your central nervous system arise. Here’s what you need to know about it. If your physician suspects ...